Business Wire

GN-HEARING

2.4.2020 10:41:08 CEST | Business Wire | Press release

Share
GN Hearing partners with hearing care professionals to launch a game-changing telehealth solution: New innovative at-home access to hearing aids and care

GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service. At a time when elderly, more vulnerable populations are advised to stay home, this innovative telehealth solution enables people, from the comfort and safety of their home, to connect with their hearing care professional for new hearing aids and care remotely.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005306/en/

GN Hearing recognizes that COVID-19 may seriously affect people who use hearing aids due to stricter social distancing measures, ultimately affecting many people’s wellbeing and mental health. Telehealth services can make an important difference in helping people stay connected with loved ones and informed on rapidly changing events while staying at home. People do not have to sacrifice their hearing and can get the help they need to hear better.

With the launch of ReSound Assist Live, people can now have new hearing aids adjusted remotely by their hearing care professional via new at-home video consultations without physically going to a clinic. Additionally, in these difficult times, hearing care professionals can provide new hearing aids for those who have recently completed a hearing test. In collaboration with HearX, a digital health care company focused on mobile hearing screening, testing and video otoscopy, hearing care professionals in the US can also offer drive-through or at-home hearing tests and receive adjustments and counseling via ReSound Assist Live.

“At this critical time, GN Hearing is as committed as always to helping the hearing community where it’s most needed. For many people, staying in touch with loved ones on the phone and online demands great hearing abilities, so getting access to hearing care support is crucial, particularly for those in self-isolation when communicating is imperative for an individual’s wellbeing,” says Gitte Aabo, CEO and President of GN Hearing.

ReSound Assist Live is an update to ReSound Assist, which already lets people request and receive adjustments to their hearing aids remotely, but the new telehealth tech goes further, enabling live video consultations with hearing care professionals for support wherever they are. This allows in-person support over live video and remote fitting of hearing aids all via the ReSound Smart 3D™ app.

“We expect that the introduction of ReSound Assist Live will help more hearing aid users and their hearing care professionals connect via our innovative remote solutions that work for them, regardless of what’s going on in their lives, how much mobility they have during this difficult time, and in the future,” Gitte Aabo continues.

ReSound Assist Live is available on April 2, 2020 in the US, Canada, the U.K., Germany, Australia, New Zealand and Singapore, and globally from May 1. At-home and drive-through hearing tests will be offered shortly in the US.

- ENDS -

NOTES TO EDITORS

ReSound Assist Live enables individualized care from anywhere

New ReSound Assist Live is an extension of the existing ReSound Assist remote fine-tuning services and can be accessed via video call on the ReSound Smart 3D app. It is the only fitting software which offers comprehensive live video and remote adjustment options.

ReSound Assist already lets people request and receive adjustments to their hearing aids remotely, but ReSound Assist Live goes further, enabling them to speak directly to their hearing care professional over a live link. This means they can benefit from instant access to the highest level of care at a convenient time and place.

About ReSound

ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology. ReSound was the first hearing aid brand to be Made for iPhone and pioneered the development of 2.4 GHz wireless technology. The introduction of the sixth generation of this technology with ReSound LiNX QuattroTM demonstrates that ReSound is the absolute leader in the industry. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.

About GN Group

The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).

​​Visit our homepage GN.com, get to know our innovation and leadership​ ​​, and connect with us on LinkedIn , Facebook and Twitter .

© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye